- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01998607
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
5. januar 2018 opdateret af: Amgen
Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Osteonecrosis of the Jaw (ONJ) is an adverse effect of antiresorptive therapy that is well-recognized in patients with advanced cancer.
Detailed information regarding this risk is specified in the Summary of Product Characteristics (SPC).
The statements in the SPC are the most important mechanism for minimizing the risk for ONJ.
The study objective is to measure the knowledge of oncology practitioners prescribing XGEVA® regarding the content pertaining to ONJ in the SPC after commercial availability.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a multiple cross-sectional survey study of practicing oncology practitioners prescribing XGEVA in Europe from across but not limited to the 5 largest European countries by population (including France, Germany, Italy, Spain and the U.K.) and 4 Nordic countries (Denmark, Finland, Norway and Sweden).
The survey will be conducted in two rounds.
The two survey rounds will be conducted 12 to 18 months and 24 to 30 months after XGEVA becomes commercially available in the participating countries.
The initial contact and screening of potential participating oncology practitioners will continue until a total of 210 eligible and consenting oncology practitioners complete the survey per round.
For the 5 largest European countries by population, it is intended that 30 oncology practitioners will be surveyed per country per survey round.
If this sample size cannot be achieved, oncology practitioners from another country in that region will be surveyed to achieve a regional sample size of 150 per survey round.
Oncology practitioners from the Nordic countries will be surveyed to achieve a regional sample size of 60 per survey round.
For all countires, the number of surveys collected in each country in the second survey round will, where possible, equate to the number of surveys collected in each country in the first survey round.
Undersøgelsestype
Observationel
Tilmelding (Forventet)
420
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
Oncology specialists treating adult patients with bone metastases from solid tumours
Beskrivelse
Practicing oncology specialists who have treated at least 5 adult patients with bone metastases from solid tumours in the last quarter.
Must have prescribed XGEVA® within the last 12 months.
Must not have participated in a previous survey round
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Round 1
Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
|
Eligible physicians will be contacted to perform the physician survey.
A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
Andre navne:
|
Round 2
Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
|
Eligible physicians will be contacted to perform the physician survey.
A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Proportion of participating oncology practitioners prescribing XGEVA® who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round)
Tidsramme: 12 and 24 months after commercial availability of XGEVA® in the respective country
|
12 and 24 months after commercial availability of XGEVA® in the respective country
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
4. februar 2013
Primær færdiggørelse (Faktiske)
15. maj 2015
Studieafslutning (Faktiske)
15. maj 2015
Datoer for studieregistrering
Først indsendt
25. november 2013
Først indsendt, der opfyldte QC-kriterier
25. november 2013
Først opslået (Skøn)
2. december 2013
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
9. januar 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
5. januar 2018
Sidst verificeret
1. januar 2018
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 20110102 (20110102)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Faste tumorer
-
Memorial Sloan Kettering Cancer CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
BeiGeneRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, New Zealand, Australien, Kina
-
Anjali PawarRekrutteringSolid tumor | Solid tumor, barndomForenede Stater
-
Impact Therapeutics, Inc.RekrutteringSolid tumor | Avanceret solid tumorKina, Taiwan, Forenede Stater, Australien
-
Partner Therapeutics, Inc.Trukket tilbageSolid tumor | Solid tumor, voksenForenede Stater
-
Novartis PharmaceuticalsAfsluttetKræft | Solid tumor | Avanceret solid tumorJapan
-
Pyxis Oncology, IncRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, Spanien, Belgien
-
Neurogene Inc.Merck Sharp & Dohme LLCAktiv, ikke rekrutterendeSolid tumor | Avanceret solid tumorForenede Stater, Australien, Canada
Kliniske forsøg med Physician Survey
-
University of MichiganAgency for Healthcare Research and Quality (AHRQ)Afsluttet
-
Children's Mercy Hospital Kansas CityAfsluttet
-
Henry Ford Health SystemUkendt
-
University GhentRekrutteringNakke smerter | Hovedpine | Hovedpine lidelser | Cervikal smerteBelgien
-
Gazi UniversityRekrutteringHovedpine | Hovedpine lidelser | Hovedpine, migræne | Hovedpine Kronisk | Hovedpine, spændinger | Hovedpine MuskuløsKalkun
-
Gazi UniversityRekrutteringKronisk hoftesmerter | HoftesygdomKalkun
-
George Washington UniversityAfsluttet
-
Abant Izzet Baysal UniversityIkke rekrutterer endnuKoronararteriesygdom | Overholdelse, Behandling
-
Hacettepe UniversityIkke rekrutterer endnu